The DYNC1LI1 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DYNC1LI1 gene in the K-562 human cell line. This product provides a loss-of-function model system for investigating the role of cytoplasmic dynein light intermediate chain 1, a critical subunit of the major retrograde motor complex. The polyclonal nature of the knockout population ensures representation of various editing events, collectively abrogating DYNC1LI1 protein expression and function. As a genetically defined tool, these cells support functional dissection of dynein-dependent intracellular transport and its contributions to leukemia cell biology.
The host K-562 cell line is a leukemic blast cell model established from the pleural effusion of a 53-year-old female with chronic myeloid leukemia in blast crisis. This suspension-adapted line is BCR-ABL1 positive and exhibits undifferentiated blast morphology with multipotential differentiation capability, making it a widely used system for erythroleukemia research. K-562 cells serve as a robust platform for studying hematopoietic malignancy-associated pathways, including signal transduction, cell cycle progression, and apoptotic regulation. Their genetic background and growth characteristics provide a physiologically relevant context for assessing the consequences of dynein disruption in a leukemic environment.
DYNC1LI1 encodes a light intermediate chain of the cytoplasmic dynein complex, essential for maintaining dynein stability and facilitating cargo binding during microtubule-based retrograde transport. It directly interacts with the heavy chain DYNC1H1 and dynactin subunits such as DCTN1 and DCTN2, as well as adaptor proteins BICD2, HOOK3, and TRAK1, which link dynein to specific cargos. The complex is regulated by LIS1 and NDE1/NDEL1, which control motor activity and are particularly important for mitotic spindle organization. Downstream, DYNC1LI1 governs lysosomal distribution, mitochondrial positioning, EGFR signaling endosome retrograde transport, and chromosome segregation. Thus, it integrates signals from cell cycle regulators and cargo adaptors to orchestrate organelle dynamics and genome stability.
In the context of K-562 leukemic cells, disruption of DYNC1LI1 is expected to compromise cytoplasmic dynein function, leading to defective mitotic spindle orientation and chromosome segregation errors. This mimics conditions that could promote aneuploidy and genomic instability, features commonly associated with leukemia progression. Moreover, impaired retrograde transport likely alters lysosomal and mitochondrial distribution, impacting metabolic homeostasis and stress responses. Disrupted trafficking of signaling endosomes, including those containing activated EGFR, may further perturb proliferative and survival pathways. These cellular consequences make the DYNC1LI1 knockout K-562 population a powerful model for dissecting the role of the dynein complex in leukemic cell division and intracellular organization.
This knockout cell model enables a wide range of research applications, including detailed investigation of dynein-dependent cargo transport in hematopoietic cells, analysis of mitotic defects using live-cell imaging and immunofluorescence, and functional genomics studies to map dynein interaction networks. Researchers can employ techniques such as Western blotting to confirm DYNC1LI1 loss, flow cytometry to examine cell cycle perturbations and apoptosis, and drug sensitivity assays to evaluate responses to agents like paclitaxel. Co-immunoprecipitation experiments can assess the integrity of the dynein-dynactin complex. These applications provide avenues for discovering dynein-targeted therapeutic strategies. For additional information or technical support, please contact Ascent Research.
